Clinical and translational results of a phase I study, tocilizumab plus gemcitabine/nab-paclitaxel in patient with gemcitabine/nab-paclitaxel-refractory metastatic pancreatic cancer

被引：0
|
作者：
Mitsunaga, Shuichi [1 ]
Ikeda, Masafumi [1 ]
Aoki, Kazunori [2 ]
Yamaguchi, Kyoko [3 ]
Sawada, Noriaki [4 ]
Fujii, Etsuko [4 ]
Nishidate, Masanobu [4 ]
Fujitomo, Takashi [4 ]
Mizuno, Hideaki [4 ]
Kayukawa, Yoko [4 ]
Kato, Atsuhiko [5 ]
Makikawa, Mayu [3 ]
Imaoka, Hiroshi [1 ]
Sasaki, Mitsuhito [1 ]
Watanabe, Kazuo [1 ]
Tsunoda, Hiroyuki [4 ]
Terao, Kimio [3 ]
Ochiai, Atsushi [1 ]
机构：
[1] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan
[2] Natl Canc Ctr, Tokyo, Japan
[3] Chugai Pharmaceut Co Ltd, Tokyo, Japan
[4] Chugai Pharmaceut Co Ltd, Kamakura, Kanagawa, Japan
[5] Chugai Pharmaceut Co Ltd, Shizuoka, Japan
来源：
CANCER RESEARCH | 2022年 / 82卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT565
引用
收藏
页数：2
相关论文
共 50 条
  • [41] The Role of nab-Paclitaxel Plus Gemcitabine Therapy for Recurrent Pancreatic Cancer Refractory to Gemcitabine and S-1
    Kagawa, S.
    Yoshitomi, H.
    Shimizu, H.
    Ohtsuka, M.
    Kato, A.
    Furukawa, K.
    Takayashiki, T.
    Takano, S.
    Kuboki, S.
    Suzuki, D.
    Sakai, N.
    Miyazaki, M.
    PANCREAS, 2015, 44 (08) : 1385 - 1385
  • [42] Phase Ib and Expansion Study of Gemcitabine, Nab-Paclitaxel, and Ficlatuzumab in Patients With Metastatic Pancreatic Cancer
    Perez, Kimberly
    Chiarella, Anna M.
    Cleary, James M.
    Horick, Nora
    Weekes, Colin
    Abrams, Thomas
    Blaszkowsky, Lawrence
    Enzinger, Peter
    Giannakis, Marios
    Goyal, Lipika
    Meyerhardt, Jeffrey A.
    Rubinson, Douglas
    Yurgelun, Matthew B.
    Goessling, Wolfram
    Giantonio, Bruce J.
    Brais, Lauren
    Germon, Victoria
    Stonely, Danielle
    Raghavan, Srivatsan
    Bakir, Basil
    Das, Koushik
    Pitarresi, Jason R.
    Aguirre, Andrew J.
    Needle, Michael
    Rustgi, Anil K.
    Wolpin, Brian M.
    ONCOLOGIST, 2023, 28 (05): : 425 - 432
  • [43] ECONOMIC EVALUATION OF NAB-PACLITAXEL PLUS GEMCITABINE VERSUS GEMCITABINE ALONE FOR THE MANAGEMENT OF METASTATIC PANCREATIC CANCER IN GREECE
    Fragoulakis, V
    Papakostas, P.
    Pentheroudakis, G.
    Dervenis, C.
    Maniadakis, N.
    VALUE IN HEALTH, 2014, 17 (07) : A632 - A632
  • [44] Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine in patients with advanced pancreatic cancer: a multicenter, randomized, phase II study
    Jin, Min
    Liu, Hong-Li
    Xue, Jun
    Ma, Hong
    Liu, Jun-Li
    Lin, Zhen-Yu
    Wang, Jing
    Bao, Le-Qun
    Luo, Zhi-Guo
    Yu, Xiong-Jie
    Li, Shuang
    Hu, Jian-Li
    Zhang, Tao
    ONCOLOGIST, 2024,
  • [45] Phase I study of nivolumab (Nivo) plus nab-paclitaxel (nab-P) plus gemcitabine (Gem) in advanced pancreatic cancer (APC).
    Wainberg, Zev A.
    Hochster, Howard S.
    Kim, Edward Jae-Hoon
    George, Ben
    Kalyan, Aparna
    Chiorean, E. Gabriela
    Waterhouse, David Michael
    Gutierrez, Martin
    Parikh, Aparna Raj
    Jain, Rishi
    Carrizosa, Daniel R.
    Soliman, Hatem Hussein
    Bhore, Rafia
    Banerjee, Sibabrata
    Lyons, Larry
    Louis, Chrystal Ursula
    Ong, Teng Jin
    O'Dwyer, Peter J.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [46] Phase I/II study of nab-paclitaxel plus gemcitabine for chemotherapy-naive Japanese patients with metastatic pancreatic cancer
    Ueno, Hideki
    Ikeda, Masafumi
    Ueno, Makoto
    Mizuno, Nobumasa
    Ioka, Tatsuya
    Omuro, Yasushi
    Nakajima, Takako Eguchi
    Furuse, Junji
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 77 (03) : 595 - 603
  • [47] NAB-PACLITAXEL IN THE TREATMENT OF ADVANCED PANCREATIC CANCER REFRACTORY TO GEMCITABINE - FINAL RESULTS OF A PHASE 2 TRIAL
    Lopes, G. de Lima
    Hosein, P.
    Gomez, C.
    Pastorini, V.
    Macintyre, J.
    Easey, M.
    Reis, I.
    Merchan, J.
    Bejarano, P.
    Rocha-Lima, C.
    EJC SUPPLEMENTS, 2011, 9 (01): : 1 - 1
  • [48] Phase I/II study of nab-paclitaxel plus gemcitabine for chemotherapy-naive Japanese patients with metastatic pancreatic cancer
    Hideki Ueno
    Masafumi Ikeda
    Makoto Ueno
    Nobumasa Mizuno
    Tatsuya Ioka
    Yasushi Omuro
    Takako Eguchi Nakajima
    Junji Furuse
    Cancer Chemotherapy and Pharmacology, 2016, 77 : 595 - 603
  • [49] Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma
    Weiss, Glen J.
    Blaydorn, Lisa
    Beck, Julia
    Bornemann-Kolatzki, Kirsten
    Urnovitz, Howard
    Schutz, Ekkhard
    Khemka, Vivek
    INVESTIGATIONAL NEW DRUGS, 2018, 36 (01) : 96 - 102
  • [50] Alternating gemcitabine plus nab-paclitaxel and gemcitabine alone versus continuous gemcitabine plus nab-paclitaxel after induction treatment of metastatic pancreatic cancer (ALPACA): a multicentre, randomised, open-label, phase 2 trial
    Dorman, Klara
    Boeck, Stefan
    Caca, Karel
    Reichert, Maximilian
    Ettrich, Thomas J.
    Oettle, Helmut
    Waidmann, Oliver
    Modest, Dominik P.
    Mueller, Lothar
    Michl, Patrick
    Kanzler, Stephan
    Pink, Daniel
    Reinacher-Schick, Anke
    Geissler, Michael
    Pelz, Henning
    Kunzmann, Volker
    Held, Swantje
    Schichtl, Thomas
    Heinemann, Volker
    Kullmann, Frank
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2024, 9 (10): : 935 - 943
12345